The Endocrine Society has officially announced the opening of the application period for the position of Editor-in-Chief of its flagship publication, The Journal of Clinical Endocrinology & Metabolism (JCEM). This prestigious leadership role, which oversees one of the most influential peer-reviewed journals in the medical field, is scheduled to accept applications from November 1 through November 30, 2026. The selected candidate will be tasked with steering the journal’s editorial direction for a three-year term beginning January 1, 2028, with a critical transition and preparatory period commencing in the summer of 2027.
As the preeminent venue for clinical endocrine research, JCEM serves as a global conduit for developments in diabetes, metabolism, and various hormonal disorders. The search for a new Editor-in-Chief (EIC) comes at a pivotal time for medical publishing, as the industry grapples with the integration of artificial intelligence in research, the transition toward open-access models, and the increasing need for diversity in clinical trial representation. The Endocrine Society’s call for applications emphasizes the need for an internationally recognized researcher who possesses both the scientific acumen to evaluate high-level research and the visionary leadership to maintain the journal’s status as a top-tier publication.
A Legacy of Clinical Excellence and Scientific Influence
The Journal of Clinical Endocrinology & Metabolism has long been regarded as a cornerstone of the endocrine community. Founded to provide a dedicated space for clinical investigations, the journal has evolved alongside the field of endocrinology itself. Today, it focuses on the pathophysiology, diagnosis, and treatment of endocrine and metabolic disorders, bridging the gap between bench science and bedside application.
The importance of the journal is underscored by its recent performance metrics. In 2025, JCEM recorded more than 83,000 citations, solidifying its position as the second most-cited journal among the 200 publications listed in the Clarivate category of “Endocrinology & Metabolism.” This high citation rate reflects the journal’s role in shaping clinical guidelines and informing the standard of care for millions of patients worldwide. For the incoming Editor-in-Chief, maintaining this level of influence requires a delicate balance of rigorous peer-review standards and a forward-looking approach to emerging scientific trends.
The journal’s scope is expansive, covering a wide array of sub-specialties. These include, but are not limited to, thyroid disorders, adrenal health, reproductive endocrinology, pediatric endocrinology, and bone and mineral metabolism. By providing a platform for investigators from around the globe, JCEM ensures that the latest breakthroughs in clinical research reach practitioners and academics alike, fostering a continuous cycle of medical improvement.
Detailed Responsibilities and Leadership Structure
The Editor-in-Chief position is a remote, institution-based role that requires close collaboration with the Endocrine Society’s headquarters in Washington, D.C. While the EIC remains based at their home academic or clinical institution, they are integrated into the Society’s organizational framework, working alongside the Publications Core Committee and professional staff.
The primary responsibility of the EIC is to provide the overarching vision for the journal. This involves selecting a high-caliber team of Deputy Editors (DEs) and Associate Editors (AEs) to manage the vast influx of manuscript submissions. The EIC must ensure that the peer-review process remains objective, efficient, and transparent. Furthermore, the EIC is responsible for the final decisions on high-impact papers that have the potential to change clinical practice.
The leadership structure is designed to be robust. Supported by an Executive Editor and a dedicated publications staff, the EIC manages the editorial board’s composition, ensuring it reflects the global and diverse nature of the endocrine field. The role also involves periodic reporting to the Society’s leadership regarding the journal’s performance, impact factor trends, and strategic goals. To support these efforts, the Society provides a stipend and a travel allowance, acknowledging the significant time and professional commitment required to lead such a high-profile publication.
Timeline and Transition Strategy
The search and appointment process for the JCEM Editor-in-Chief is structured to ensure a seamless transition of leadership. This long-lead approach is standard for high-impact medical journals, allowing the incoming editor to familiarize themselves with the journal’s internal systems and editorial workflows before taking full responsibility.
- November 1 – November 30, 2026: The formal application window is open. Candidates must submit their materials, including a comprehensive curriculum vitae and a vision statement for the journal’s future, by the November 30 deadline (5:00 pm ET).
- Early 2027: The Search Committee, composed of distinguished members of the Endocrine Society and experts in the field, will evaluate the candidates. This evaluation is based on several criteria, including research prominence, editorial experience, and the ability to work collaboratively within the Society’s framework.
- Mid-2027: The Editor-in-Chief-elect is announced. During this period, the incoming EIC begins preparatory work. This involves shadow-editing, attending editorial board meetings, and beginning the process of recruiting their team of Deputy and Associate Editors.
- January 1, 2028: The three-year term officially begins. The new EIC assumes full control of the journal’s editorial content and strategic direction.
This chronology ensures that there is no disruption in the publication cycle or the quality of the peer-review process during the leadership change.
Supporting Data: The Journal’s Market Position
The significance of the JCEM EIC role is best understood through the lens of the journal’s historical and current data. Endocrinology as a field has seen an explosion of research interest due to the global rise in metabolic diseases, such as Type 2 diabetes and obesity. Consequently, the demand for high-quality clinical data has never been higher.
In the 2025 Clarivate rankings, JCEM’s 83,000+ citations placed it at the very top of its peer group, surpassed by only one other journal in the “Endocrinology & Metabolism” category. This metric is a key indicator of the journal’s "stickiness" and relevance; researchers not only read JCEM but also rely on its findings to support their own work. The journal’s impact factor, while just one of many metrics, remains a vital sign of its prestige, attracting the world’s leading investigators to submit their best work.
Furthermore, the journal’s global reach is evidenced by the geographic diversity of its contributors. With submissions coming from every continent, the new EIC must be prepared to navigate various international standards for clinical trials and ethical considerations, further emphasizing the need for an "internationally recognized" leader as specified in the Society’s call for applications.
Strategic Implications and Inferred Industry Reaction
The announcement of the search for a new EIC has been met with significant interest within the academic community. While the Endocrine Society has not released formal statements from individual board members, the consensus among industry observers is that the next EIC will need to be a "digital-first" leader.
Inferred reactions from the broader medical publishing community suggest that the new EIC will face three primary challenges:
- The Open Access Movement: As more funding agencies mandate open-access publication, the EIC will need to work with the Society to ensure JCEM remains financially viable while expanding access to its content.
- Artificial Intelligence: The rise of AI-generated content and AI-assisted research requires the development of new editorial policies to protect the integrity of the scientific record.
- Clinical Trial Diversity: There is a growing mandate in clinical endocrinology to ensure that research participants reflect the diverse populations affected by endocrine disorders. The new EIC will likely be expected to prioritize studies that address health disparities.
Analysis suggests that the Search Committee will look for a candidate who has not only published extensively but has also demonstrated a commitment to these evolving standards. The ability to innovate the journal’s delivery—perhaps through increased use of multimedia, podcasts, and interactive data—will also likely be a factor in the selection process.
Application Criteria and Submission Guidelines
The Endocrine Society has outlined a rigorous set of criteria for potential candidates. Applicants are expected to be members of the Endocrine Society and should be prepared to demonstrate a history of forward-looking leadership. The evaluation process will focus on the candidate’s ability to maximize the journal’s impact and success in an increasingly competitive publishing environment.
Candidates are required to submit their applications to Windy Boyd, the Executive Editor of the journal. The application packet typically includes a detailed letter of interest, a full CV, and a strategic vision for the journal. This vision statement is often the most critical component, as it allows the Search Committee to assess how the candidate intends to navigate the aforementioned challenges of the modern publishing landscape.
The Endocrine Society encourages its members to not only consider applying themselves but to also nominate and share the announcement with suitable colleagues who possess the requisite expertise and leadership qualities.
The Broader Impact on Global Health
The appointment of a new Editor-in-Chief for JCEM is more than an internal administrative change; it is an event with implications for global health. Because JCEM publishes the research that eventually becomes the basis for clinical guidelines, the editorial decisions made by the EIC directly influence how doctors treat patients with diabetes, thyroid cancer, growth disorders, and more.
Under the right leadership, JCEM can accelerate the adoption of precision medicine in endocrinology, promote better diagnostic tools for rare metabolic diseases, and ensure that clinical research is conducted with the highest ethical standards. The Endocrine Society’s commitment to a transparent and thorough search process ensures that the journal will continue to serve as a beacon of scientific integrity and clinical progress for years to come.
As the November 2026 deadline approaches, the global endocrine community will be watching closely. The individual selected to lead The Journal of Clinical Endocrinology & Metabolism from 2028 through 2030 will inherit a legacy of excellence and a platform of immense power to shape the future of medical science.
